Back
Informatica 10K Form
Buy
52
INFA
Informatica
Last Price:
$24.32
Seasonality Move:
-3.32%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-02 | 10Q | INFA/Informatica Quarterly |
2023-11-02 | 10Q | INFA/Informatica Quarterly |
2023-08-03 | 10Q | INFA/Informatica Quarterly |
2023-05-04 | 10Q | INFA/Informatica Quarterly |
2022-11-10 | 10Q | INFA/Informatica Quarterly |
2022-08-04 | 10Q | INFA/Informatica Quarterly |
Receive INFA News And Ratings
See the #1 stock for the next 7 days that we like better than INFA
INFA Financial Statistics
Sales & Book Value
Annual Sales: | $1.6B |
---|---|
Cash Flow: | $151M |
Price / Cash Flow: | 17.73 |
Annual Sales: | $7.55 |
Price / Book: | 3.22 |
Profitability
EPS (TTM): | 0.00000 |
---|---|
Net Income (TTM): | $1.9M |
Gross Margin: | $1.3B |
Return on Equity: | 0.08% |
Return on Assets: | 0.04% |
Informatica Earnings Forecast
Key Informatica Financial Ratios
-
The Gross Profit Margin over the past 17 years for INFA is 80.11%.
-
The Selling, General & Administrative Expenses for INFA have been equal to 44.95% of Gross Profit Margin.
-
The Research & Development expenses have been 19.22% of Revenue.
-
The Interest Expense is 1,470.79% of Operating Income.
-
The Net Earning history of INFA is 0.61% of Total Revenues.
-
Per Share Earnings over the last 17 years have been positive in 11 years.
Informatica Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Software |
Sector: | Information Technology |
Current Symbol: | INFA |
CUSIP: | 45666Q |
Website: | informatica.com |
Debt
Debt-to-Equity Ratio: | 0.79 |
---|---|
Current Ratio: | 1.92 |
Quick Ratio: | 1.71 |
Price-to-Earnings
Trailing P/E Ratio: | 810.67 |
---|---|
Forward P/E Ratio: | 18.89 |
INFA Technical Analysis vs Fundamental Analysis
Buy
52
Informatica (INFA)
is a Buy
Is Informatica a Buy or a Sell?
-
Informatica stock is rated a BuyThe current Informatica [INFA] share price is $24.32. The Score for INFA is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.